This early-stage study tested an experimental vaccine called AV-1959R in 16 healthy adults aged 40 to 60. The goal was to see if the vaccine is safe and can trigger an immune response against a protein linked to Alzheimer's disease. Participants received three shots over 14 weeks…
Phase: PHASE1 • Sponsor: Nuravax, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:56 UTC